ReviewLife (Basel, Switzerland)2023
Left Ventricular Assist Device as a Destination Therapy: Current Situation and the Importance of Patient Selection.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Exploring patient, caregiver and care team experiences of destination therapy Left Ventricular Assist Device (LVAD): A multiple case qualitative study protocol.International journal of nursing studies advances · 2026Article
- Telling is Caring: Prioritizing the Best Interests of Dying Children.HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues · 2026Article
- Worldwide research trends on left ventricular assist devices for heart failure: a bibliometric analysis.Journal of cardiothoracic surgery · 2026Review
- Early clinical outcomes and quality of life assessment after HeartMate 3 implantation: A single-centre descriptive study.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2026Article
- Identifying key CT features and clinical variables for predicting operative management of left ventricular assist device (LVAD) driveline infections.Emergency radiology · 2025Article
- A heart failure center model helped to promote the standardized management and improve the prognosis of patients.Cardiovascular diagnosis and therapy · 2025Article
- Survival of a patient following initial left ventricular assist device implantation and two successive left ventricular assist device exchanges: case report.European heart journal. Case reports · 2024Article
- Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries.Life (Basel, Switzerland) · 2024Article
- Left Ventricular Assist Device in Advanced Refractory Heart Failure: A Comprehensive Review of Patient Selection, Surgical Approaches, Complications and Future Perspectives.Diagnostics (Basel, Switzerland) · 2024Review
- Heart Transplantation and Left Ventricular Assist Devices: Long-Term Prognosis and Effects on Mental Health.Cureus · 2024Review
- Age Is a Predictor of In-Hospital Outcomes for Left Ventricular Assist Device Implantation: A Nationwide Analysis.Journal of personalized medicine · 2024Article
- Device therapies for heart failure with reduced ejection fraction: a new era.Frontiers in cardiovascular medicine · 2024Review
- How to Select Patients for Left Ventricular Assist Devices? A Guide for Clinical Practice.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced heart failure is a growing problem for which the best treatment is cardiac transplantation. However, the shortage of donors' hearts made left ventricular assist devices as destination therapy (DT-LVAD) a highly recommended alternative: they improved mid-term prognosis as well as patients' quality of life. Current intracorporeal pumps with a centrifugal continuous flow evolved in the last few years. Since 2003, when first LVAD was approved for long-term support, smaller device sizes with better survival and hemocompatibility profile were reached. The most important difficulty lies in the moment of the implant. Recent indications range from INTERMACS class 2 to 4, with close monitoring in intermediate cases. Moreover, a large multiparametric study is needed for considering the candidacy: basal situation, with a special interest in frailty, comorbidities, including renal and hepatic dysfunction, and medical background, considering every prior cardiac condition, must be evaluated. In addition, some clinical risk scores can be helpful to measure the possibility of right heart failure or morbi-mortality. With this review, we sought to summarize all the device improvements, with their updated clinical results, as well as to focus on all the patient selection criteria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.